Option FanaticOptions, stock, futures, and system trading, backtesting, money management, and much more!

BKNG Stock Study (10-25-26)

I recently studied Booking Holdings, Inc. (BKNG, $155.83). The previous study is here.

M* writes:

     > Booking is the world’s largest online travel agency by
     > sales, offering booking and payment services for hotel
     > cars, and alternative accommodation rooms, airlines, rental
     > restaurants, cruises, experiences, and other vacation
     > packages. The company operates several branded travel
     > booking sites, including Booking.com, Agoda, OpenTable,
     > Rentalcars.com, and Kayak. Transaction fees for online
     > bookings account for the bulk of revenue and profits.

Over the past decade, this large-size company has grown sales and EPS at annualized rates of 9.6% and 14.3%, respectively (excluding 2020-21 from the entire study due to COVID-19). Lines are mostly up, straight, and parallel except for EPS decline in ’22 and EPS dip in ’25. Five- (10-) year EPS R^2 is 0.85 (0.76), but Value Line (VL) only gives an Earnings Predictability score of 30. Shares outstanding decrease 34.8% (4.6% per year).

Over the past decade, PTPM leads peer averages and lags the industry while ranging from 23.0% in ’22 to 39.5% in ’19 with a last-5-year mean of 26.2%. ROE is roughly even with peer and industry averages despite being [NMF] high or triple-digit negative in different years due mainly to the massive share buybacks mentioned above. Last-5-year-ROE mean is -209% (shareholder equity starts to decline in 2018 and turns negative in ’23). Debt-to-capital is less than industry averages but greater than peers with a last-5-year mean of 108% [last three sentences make my head hurt].

[Despite the headache] Quick ratio is 1.0 and interest coverage 8.7 per M* who assigns “Wide” Economic Moat, “Exemplary” Capital Allocation, and a B grade for Financial Health (per BI website). VL gives a B++ rating for Financial Strength.

RightStock—a new tool on the BI website that I am tracking for informational purposes—gives a fitness score of 57 (“poor”). It cites weak or declining earnings: I disagree. It cites poor/weak ROE and poor debt-to-capital. While I agree with the latter, this is a management/directors business model decision. In exchange for substantial share buybacks thereby bolstering EPS, ROE is NMF (basically) and debt-to-capital looks freakishly high. As mentioned above, interest coverage is 6 [VL] to 8x—quite safe–and over 36x when taking into account the $17B cash stash that generates significant interest on its own.

With regard to sales growth:

My 8.0% forecast is below the range.

With regard to EPS growth:

My 12.0% per year forecast is below the long-term-estimate range (mean of eight: 15.2%). Initial value is ’25 EPS of $6.62/share rather than 2026 Q2 $9.03 (TTM).

My Forecast High P/E is 26.0. Over the past 10 years, high P/E ranges from 18.6 in ’19 to 44.1 in ’17 with last-5-year mean of 33.1 and a last-5-year-mean average P/E of 26.7. I am near bottom of the range (only ’19 is less).

My Forecast Low P/E is 16.0. Over the past 10 years, low P/E ranges from 14.6 in ’19 to 31.2 in ’17 with a last-5-year mean of 20.4. I am forecasting near bottom of the range (only ’19 is less).

My Low Stock Price Forecast (LSPF) of $105.90 is default based on initial value from above: 32.0% less than previous close and 29.4% less than the 52-week low (perhaps excessive).

Company starts paying dividend with payout ratio (PR) of 20.3% and 23.2% in ’24 and ’25, respectively. Being so new, I am forecasting below the range at 10.0%.

These inputs land BKNG in the BUY zone with a U/D ratio of 3.0. Total Annualized Return (TAR) is 14.6%.

PAR (using Forecast Average—not High—P/E) of 10.0% is less than I seek for a large-size company. If a solid margin of safety (MOS) backs this study, then I can proceed based on TAR instead.

To assess MOS, I start by comparing my inputs with those of Member Sentiment (MS). Based on 64 studies done in the past 90 days (my study and 23 outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, Forecast Low P/E, and PR are 9.0%, 14.2%, 29.4, 19.3, and 15.9%, respectively. I am lower across the board. VL projects a future average P/E of 20.0 that is less than MS (24.4) and less than mine (21.0).

MS high / low EPS are $16.28 / $8.63 versus my $11.67 / $6.62 (per share). My high EPS is less due to primarily to a lower initial value. VL (M*) high EPS of $16.80 ($17.82) is greater than both.

MS LSPF of $143.00 implies a Forecast Low P/E of 16.6: less than the above-stated 19.3. MS LSPF is 14.1% less than the default $8.63/share * 19.3 = $166.56 resulting in more conservative zoning. MS LSPF is still 35.0% greater than mine.

MOS is robust in the study because my inputs are below/near most historical/analyst/MS estimates and ranges. Supporting the MOS is MS TAR exceeding mine by 7.4% (too high, perhaps) per year and my substantially lower LSPF.

With regard to valuation, PEG is 0.96 and 1.3 per Zacks and my projected P/E, respectively: fairly valued (0.20 per M* seems unreasonably low). Relative Value [(current P/E) / 5-year-mean average P/E] is quite cheap at 0.65. “Quick and dirty” cash flow has stock undervalued by 40% (with capex and dividend excluded, even). M* reports stock at a 28% discount.

Per my SSG, BKNG is a U/D BUY right now under $155 share. [303.4 / ((14.47 / 100 ) +1 ) ^ 5] ~ $154 meets the BetterInvesting® TAR criterion given forecast high price ~$303.

A 90-day free trial to BetterInvesting® may be secured here (also see link under “Pages” section at top right of this page).

No comments posted.

Leave a Reply

Your email address will not be published. Required fields are marked *